{
 "name": "中化控股",
 "slug": "tw-3716",
 "aliases": [
  "中化控股股份有限公司",
  "Cenra Inc.",
  "3716"
 ],
 "ticker": "3716",
 "industry": "生技醫療業",
 "website": "https://www.cenra.com/",
 "summary": "中化控股（3716）是上市的生技醫療類股公司，2024 年成立，2024 年上市。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "中化控股股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "英文簡稱",
   "value": "Cenra Inc.",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "掛牌市場",
   "value": "臺灣證券交易所上市",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "上市日期",
   "value": "2024-09-02",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "成立日期",
   "value": "2024-09-02",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "董事長",
   "value": "王謝怡貞",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "總經理",
   "value": "王厚凱(執行長)",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "實收資本額",
   "value": 1505792110,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "公司網址",
   "value": "https://www.cenra.com/",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap03_L"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 674886,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap05_L",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of一致並保留；出表日1151017。僅更正source及補此note。"
  },
  {
   "claim": "月營收年增率（2026-09）",
   "value": -11.05,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap05_L",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of一致並保留；出表日1151017。僅更正source及補此note。"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": -3.2,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://openapi.twse.com.tw/v1/opendata/t187ap05_L",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of一致並保留；出表日1151017。僅更正source及補此note。"
  },
  {
   "claim": "主要產品：Duloxetine",
   "value": "精神科領域核心產品；2025年前三季法說列示",
   "unit": "",
   "as_of": "2025-12-24",
   "source": "https://www.cenra.com/uploads/images/Invester/law-meeting/114Q4.pdf",
   "note": "資料為法說當時產品組合；未據此推定許可證字號或目前販售狀態。"
  },
  {
   "claim": "主要產品：Dasatinib",
   "value": "子公司中化裕民重點推廣之高價值處方新品",
   "unit": "",
   "as_of": "2025-12-24",
   "source": "https://www.cenra.com/uploads/images/Invester/law-meeting/114Q4.pdf",
   "note": "資料為法說當時產品組合；未據此推定許可證字號或目前販售狀態。"
  },
  {
   "claim": "主要產品：Abiratred",
   "value": "子公司中化裕民重點推廣之高價值處方新品",
   "unit": "",
   "as_of": "2025-12-24",
   "source": "https://www.cenra.com/uploads/images/Invester/law-meeting/114Q4.pdf",
   "note": "資料為法說當時產品組合；未據此推定許可證字號或目前販售狀態。"
  },
  {
   "claim": "主要產品：Spikevax",
   "value": "子公司共同推廣之莫德納mRNA呼吸道疫苗；COVID-19疫苗",
   "unit": "",
   "as_of": "2026-04-21",
   "source": "https://www.cenra.com/uploads/images/Invester/annual-report/2025.pdf",
   "note": "年報重要契約載共同推廣期間2024-10-01至2027-07-31；屬合作推廣，未當成授權交易。"
  },
  {
   "claim": "主要產品：mRESVIA",
   "value": "子公司共同推廣之莫德納mRNA呼吸道疫苗；RSV疫苗",
   "unit": "",
   "as_of": "2026-04-21",
   "source": "https://www.cenra.com/uploads/images/Invester/annual-report/2025.pdf",
   "note": "年報重要契約載共同推廣期間2024-10-01至2027-07-31；屬合作推廣，未當成授權交易。"
  }
 ],
 "provided_by": "public_sources",
 "verified_at": "2026-10-22",
 "url": "https://drugnews.com.tw/companies/tw-3716.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}